Scott Boyle is a life science executive with strategic and operational experience spanning business & corporate development, management consulting, new product development, policy (regulation and reimbursement), and research. He joined Forma Therapeutics as Vice President, Business and Corporate Development, in August 2019 where he is focused on partnering and company strategy. Most recently as an Associate Director at the Boston Consulting Group, Scott served clients in oncology and precision medicine, including developing business plans for new company creation in CAR-T therapy, advising on potential investments in precision medicine companies, and analyzing key trends to inform oncology therapeutic strategies. Prior to BCG, Scott established the Business Development efforts at Caris Life Sciences, a tumor profiling company, where he commercialized Caris’ molecular data assets, proprietary discovery platform, and laboratory capabilities into precision medicine services, products, and collaborations with biopharma and data companies. Earlier in his career, Scott advised the US Secretary of Health and Human Services on science-related policy issues in precision medicine.

Scott holds a BS in Biochemistry from Brigham Young University, a Ph.D. in Molecular Biophysics and Biochemistry from Yale University, and an MBA from the Harvard Business School. He completed his Postdoctoral Fellowship at the Novartis Institute for BioMedical Research.